Evaluation of Histologic and Endoscopic Remission Induced by Infliximab in Moderate to Severe Ulcerative Colitis

NCT01408810 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Ulcerative Colitis

Interventions

DRUG: Infliximab

Sponsor

Grupo de Estudo da Doença Inflamatória Intestinal